Matthew Farabaugh is the Chief Financial Officer of The Center for Breakthrough Medicines. Matt has over 19 years of finance and business experience in clinical and basic research of immunology, oncology, cell and gene therapy, and infectious diseases. He was previously Finance Manager at WuXi Advanced Therapies where he was responsible for revenue and contract management of $100MM in US revenue for research, manufacturing, and testing portfolio related to cell and gene therapy products. Prior to this Matthew served as a member of the UPENN-Novartis Global Program Team under Dr. Carl June and was responsible for a $50MM annual clinical development plan focused on FDA approval of cutting-edge CAR T cell therapy Kymriah in pediatric patients with relapsed acute lymphoblastic leukemia. He has a BS in Microbiology from Duquesne University, an MS in Molecular Biotechnology from the University of Pennsylvania and finance training from the Wharton School of Business.
Chief Financial Officer